Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $62.78.

A number of brokerages have weighed in on HALO. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Benchmark reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Finally, Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock valued at $1,754,451 in the last quarter. 2.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $60.98 on Tuesday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics has a 52-week low of $37.73 and a 52-week high of $65.53. The business’s 50-day moving average price is $55.70 and its 200 day moving average price is $54.77. The firm has a market cap of $7.51 billion, a P/E ratio of 17.78, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, equities research analysts expect that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.